Visium Asset Management’s GenMark Diagnostics, Inc GNMK Stock Holding History

Visium Asset Management’s Portfolio GNMK Stock Details GNMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-35,235	Closed	-$307K	–	237
2016 Q2	$307K	Sell	35,235 -264,765	-88%	-$1.82M	0.02%	294
2016 Q1	$1.58M	Hold	300,000	–	–	0.03%	406
2015 Q4	$2.33M	Sell	300,000 -397,413	-57%	-$3.05M	0.04%	388
2015 Q3	$5.49M	Buy	697,413 +313,147	+81%	+$2.9M	0.08%	277
2015 Q2	$3.48M	Buy	384,266 +400	+0.1%	+$4.03K	0.05%	346
2015 Q1	$4.98M	Sell	383,866 -671,507	-64%	-$8.78M	0.07%	263
2014 Q4	$14.4M	Buy	1,055,373 +217,927	+26%	+$2.44M	0.2%	91
2014 Q3	$7.51M	Buy	837,446 +50,978	+6%	+$549K	0.11%	191
2014 Q2	$10.6M	Sell	786,468 -179,067	-19%	-$1.87M	0.17%	123
2014 Q1	$9.6M	Buy	965,535 +48,324	+5%	+$600K	0.16%	125
2013 Q4	$12.2M	Buy	917,211 +136,767	+18%	+$1.66M	0.24%	83
2013 Q3	$9.48M	Buy	+780,444	New	+$8.37M	0.22%	77

Other funds holding GNMK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Visium Asset Management's GNMK Position: Q3 2016 in Review

Visium Asset Management sold out of GenMark Diagnostics, Inc (GNMK) in Q3 2016, closing a stake of 35,235 shares — an estimated $307K sold.

Visium Asset Management first reported a position in GNMK in Q3 2013 and held it in 12 quarters. The position peaked at $14.4M in Q4 2014. 91 funds tracked by Wall St. Rank hold GNMK as of Q3 2016.

Visium Asset Management reported no remaining GenMark Diagnostics, Inc position as of Q3 2016 after selling out during the quarter.
Visium Asset Management sold 35,235 GenMark Diagnostics, Inc shares in Q3 2016, an estimated $307K.
Visium Asset Management first reported a position in GenMark Diagnostics, Inc in Q3 2013 and held it in 12 quarters.
Visium Asset Management's GenMark Diagnostics, Inc position peaked at $14.4M in Q4 2014.
91 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q3 2016.

Based on Visium Asset Management's 13F filing for Q3 2016.